[Effect of naproxen on serum concentrations of IL-I, IL-6, and TNF in patients with osteoarthritis].
OBJECTIVE
Non-steroid anti-inflammatory drugs can inhibit bone loss and preserve bone mineral density in in vitro models by inhibiting prostaglandins and inflammatory cytokines. Naproxen inhibits prostaglandin and cytokine biosynthesis. Our objective was to assess the effect of naproxen on the serum levels of IL-I, IL-6 and TNF in 18 patients with osteoarthritis.


METHODS
Two groups of nine patients each were formed randomly. One of them received naproxen 10 mg/kg BW bid for 2 weeks, and the other received placebo and paracetamol as needed. Cytokines were measured before and 2 weeks after naproxen administration by ELISA test.


RESULTS
Serum IL-I and IL-6 levels were reduced in the group receiving naproxen, suggesting a reduction of the degenerative changes in the patients with osteoarthritis, that may prevent the progression of the disease.
Martínez Cairo
S
S
División de Investigación Clinica, Coordinación de Investigación Médica, Centro Médico Nacional Siglo XXI, IMSS.
Salgado Legorreta
C
C
Martínez Zurita
F
F
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000097:blood* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D009288:Naproxen